Protocol Ledger

NCT06089278 · Phase II · COMPLETED

A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.

Interventional Phase II clinical trial protocol NCT06089278 sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-12-28 Enrollment: 160 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06089278
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)160 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06089278
Protocol FieldVerified Registry Value
NCT IdentifierNCT06089278
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment160 participants (ACTUAL)
Registered Start Date2023-12-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06089278
Hospital Research SiteLocationSite Profile
Beijing HospitalBeijing, ChinaOpen Hospital Dossier ->
Beijing Tongren Hospital, Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->
Lanzhou University Second HospitalLanzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI